| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Record information and status
Record ID
Date of creation
2018-02-27 21:10 UTC (dina.abdelhakim@cbd.int)
Date of publication
2018-02-27 21:10 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Transformation event
Oncolys BioPharma Inc
Toranomon Towers Office,
4-1-28 Toranomon, Minato-ku
Japan, 105-0001
Url:Oncolys BioPharma
Telomelysin or OBP-301 is oncolytic adenovirus in which the wild-type viral DNA is modified to be able to selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor epitopes and provides costimulatory danger signals.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Human mastadenovirus C, type 5 - HAdV-C
Characteristics of the transformation process
Techniques used for the modification
  • Transfection
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Telomerase reverse transcriptase gene promoter - Homo sapiens - HUMAN
Internal Ribosome Entry Sequence - Cardiovirus A - Cardiovirus A, EMCV
Notes regarding the genetic elements introduced or modified in this LMO
The Adenovirus Type 5 virus was genetically modified by the deletion of the wild-type E1 transcriptional unit and replacing it with a 3843 base pair insertion comprising a new E1 transcriptional unit in which the native adenovirus E1 transcriptional promoter is replaced by the human telomerase reverse transcriptase (hTERT) promoter, and an internal ribosome entry sequence (IRES) is inserted between the E1A and E1B genes.
LMO characteristics
Modified traits
  • Changes in physiology and/or production
Common use(s)
  • Pharmaceutical

Records referencing this document (2)
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record